Pfizer moved to the center of options markets today. The pharma giant's Phase 3 Sigvie-002 trial missed its primary endpoint. The drug failed to beat docetaxel in advanced non-small cell lung cancer. That headline landed hard — and options traders moved fast.
PFE has 11 active expiry dates running out to September 18. Near-term expiries on June 24 and June 26 show the most immediate positioning. Short interest sits at 3.05% of free float. That's up from 2.69% in late May. Bears are adding, not retreating.
Meanwhile, Avis Budget Group carries a striking 44.3% short interest. The company just settled a Section 16(b) lawsuit with Pentwater for $650 million in cash. Options run from tomorrow's June 23 expiry all the way through September. That settlement removes legal uncertainty. It may spark a short covering scramble.
Applied Digital also demands attention. Short interest stands at 30.2% of free float. Today the company signed a power deal with MDU Resources for its AI data center in North Dakota. Bulls loaded up call expiries through September. Availability of shares to borrow sits at 65% of SI — squeeze conditions remain live.
Primoris Services slashed its full-year EPS guidance from $4.15 to just $1.57 at the midpoint. Only three expiry dates exist — July through September. The thin options chain means any big move amplifies fast.
NVDA holds the most complex options structure of the group. It has 27 expiry dates stretching to September 18. That density signals active hedging and speculative positioning into what remains a volatile chip sector.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
